EQT’s £9.4 Billion Final Gambit for Intertek: A Stress Test for UK Public Markets

In a definitive move to consolidate the global Testing, Inspection, and Certification (TIC) landscape, Swedish private equity powerhouse EQT has raised its acquisition bid for London-listed Intertek Group to £9.4 billion ($12.8 billion). Labeled by EQT as its “final” proposal, the sweetened offer represents a strategic attempt to break a weeks-long deadlock with Intertek’s board and secure one of the largest UK public-to-private transactions of 2026.

Most “AI for Diligence” tools are lying to you. The truth is, they are just ChatGPT wrappers. Experience what real AI for Diligence looks like, built like Claude Code, but for M&A/ PE Diligence:

💼 When Claude Code Marries Due Diligence!

The revised proposal values Intertek at £61.08 per share in total consideration, a structure designed to provide immediate liquidity through a £60 cash component plus an interim dividend of 107.7 pence. This represents a significant premium over the company’s recent trading levels and follows three previous rejections from a board that has consistently argued the firm is undervalued by external suitors.

Strategic Rationale: Defensive Growth and the “TIC+” Thesis

The pursuit of Intertek highlights a broader institutional pivot toward “defensive growth” assets. In a macroeconomic environment characterized by lingering volatility, Intertek’s business model—centered on quality assurance and regulatory compliance—offers the “sticky” recurring revenue and high margins that private equity firms prize. According to recent 2026 sector outlooks from firms like Bain & Company and McKinsey, the TIC sector (or “TIC+” as some advisors now define it) is increasingly viewed as an essential infrastructure play for the global economy.

• Regulatory Tailwinds: Increasing global standards for sustainability (ESG), cybersecurity, and AI-driven compliance are driving structural demand for third-party verification.
• Operational Leverage: EQT’s internal “alpha-generating” playbook—proven in its record-breaking $20 billion monetization of Galderma—is expected to be applied here to streamline Intertek’s global laboratory network.
• Market Fragmentation: Despite its scale, the TIC industry remains fragmented. A private Intertek would likely serve as a massive “buy-and-build” platform for further consolidation of mid-cap testing firms in North America and Asia.

The Valuation Gap: Why the UK Remains a PE Hunting Ground

The bid comes at a time when the “UK valuation gap” remains a central theme for global dealmakers. As noted by Goldman Sachs and KPMG in their 2026 M&A outlooks, UK-listed mid- and large-cap companies continue to trade at a discount compared to their US and European peers. Intertek, despite a 6.7% revenue surge in Q1 2026, has seen its share price struggle to regain its 2021 peaks, making it an attractive target for sponsors with significant dry powder.

Table 1: Evolution of EQT’s Bids for Intertek (2026)

*Includes 107.7p interim dividend. Data as of May 12, 2026.

Financial Framing and Sector Implications

From a financial perspective, EQT’s offer implies an EV/EBITDA multiple that aligns with recent premiums paid for high-performing business services assets. For Intertek’s shareholders, the offer presents “certain and accelerated cash value” in a market where organic growth, while steady at mid-single digits, faces headwinds from currency fluctuations and shifting trade dynamics in the Middle East.

If successful, this delisting will signal a continued hollowing out of the FTSE 100’s industrial services sector. Competitors such as SGS and Bureau Veritas will likely face increased pressure to accelerate their own M&A strategies to maintain scale. Meanwhile, for EQT, the deal represents a cornerstone investment for its latest flagship fund, EQT XI, which is currently nearing its first close in mid-2026.

Governance and Next Steps

The Intertek board, led by CEO André Lacroix, now faces a critical decision: recommend a transaction that provides a clean exit at a premium, or hold out for a standalone recovery that may take years to materialize. Activist investors, including PrimeStone Capital, have already begun signaling their expectations for the board to engage constructively with EQT’s revised terms.

Under UK Takeover Panel rules, EQT must clarify its intentions shortly. The deal’s outcome will serve as a bellwether for cross-border M&A trends in 2026, testing whether the “finality” of private equity offers can indeed force boards of resilient UK champions to the negotiating table.

Key Deal Indicators

• Financial Advisors: Goldman Sachs and J.P. Morgan (Intertek); Morgan Stanley and SEB (EQT).
• Regulatory Hurdles: Likely minimal, given the lack of direct overlap between EQT’s current portfolio and Intertek’s core testing domains.
• Exit Strategy: A potential re-listing on the New York Stock Exchange (NYSE) or a sale to a global strategic conglomerate in 5-7 years.